FRISS
13.6.2019 07:02:06 CEST | Business Wire | Press release
Eurolife ERB, a Fairfax company, has won the IMPACT BITE (Business IT Excellence) Awards 2019 in the category IT Business Process Improvement, for its AI approach to assess risks and reduce the likelihood of fraud. The IMPACT Bite Awards is open to all companies, across industries, who have successfully integrated IT & tech systems and/or have taken initiatives in the domains of IT & Comms infrastructure that support their business goals. Eurolife ERB entered the competition with their successful implementation of the FRISS solution for automated fraud prevention. Thanks to this solution they lowered their loss ratio, enabled digital transformation and improved their customer experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190612005694/en/
Eurolife ERB, a leading player in the Greek insurance market, has the goal to reduce the risk it faces in cases of fraud involving future indemnities in the car insurance industry. Through the use of Artificial Intelligence, Eurolife ERB, in close cooperation with FRISS, has created a process of automated, more detailed risk assessment control, seeking faster, more complete and safer processing. This provides them with better customer service while contributing significantly to maintaining a net portfolio.
John Kostoglou, CIO of Eurolife ERB: “I’m very proud that we have won this award. It is great to see that our focus on innovation and digital transformation get recognized. For every insurance company the possibility of fraud is very high, in particular for contracts relating to the car industry. With the help of FRISS we are able to detect high risks and fraud in real-time. With this state-of-the art technology we save time and money for our customers.”
Simon Staadegaard, Sales Manager at FRISS, states: “We are delighted to see that our efforts to detect fraud and support honest insurance pay off. The recognition by IMPACT shows that the insurance industry really values the power of our AI solutions that are combined with our expert industry knowledge. The project with Eurolife ERB went smoothly. It was delivered on time and within budget. We look forward to a bright and fraud free future together.”
About Eurolife ERB
Eurolife ERB Insurance Group is a member of Fairfax Financial Holdings Ltd., who, through its subsidiaries, operates in insurances, reinsurance and investments’ management. Eurolife ERB Insurance Group, through its subsidiaries in Greece and Romania, designs, markets and promotes advanced products and services that meet the full range of contemporary insurance needs. Group companies in Greece include Eurolife ERB Life Insurance SA, Eurolife ERB General Insurance SA and ERB Insurance Brokers SA. A leading player in the bancassurance market, the Group has established a broad network of affiliated insurance agents across Greece. Group companies in Romania include Eurolife ERB Asigurari de Viata and Eurolife ERB Asigurari Generale. Eurolife ERB Insurance Group consistently maintains strong earnings levels and capital reserves in excess of European regulatory requirements, so as to always fulfil its responsibilities towards its clientele. Understanding its role in the society, Eurolife ERB Insurance Group is committed to give back to the communities a part of its profits per year. Through its corporate social responsibility program, the Group implements actions: (a) for quality of life and wellness, (b) for the promotion of education and culture, (c) for entrepreneurship and economy, supporting more choices and optimism for the future.
For more information, visit eurolife.gr
About FRISS
FRISS has a 100% focus on automated fraud and risk detection for P&C insurance companies worldwide. The AI-powered detection solutions for underwriting, claims and SIU have already helped 150+ insurers to grow their business. FRISS detects fraud, mitigates risks and supports digital transformation. Insurers go live within 6 months, with fixed price projects, and realize an ROI within 12 months. The FRISS solutions help to lower the loss ratio, enable profitable portfolio growth, and improve the customer experience. www.friss.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190612005694/en/
Contact:
Ruud van Gerwen PR & Product Marketer at FRISS +31 30 767 0352 Ruud.van.gerwen@friss.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press release
Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
